Pandion Pulls In $80M as Ulcerative Colitis Drug Advances in Clinic
Summary
Pandion is developing drugs intended to treat autoimmune diseases by fixing the immune system imbalance that leads to these conditions. The Cambridge, MA-based biotech’s drugs are proteins and antibodies engineered to home in on a site of autoimmune disease or inflammation. Last month, the company dosed the first patient in a Phase 1 study in ulcerative colitis, a disease characterized by inflammation of the inner lining of the large intestine. In addition to its internal R&D, Pandion also has a partnership with Astellas Pharma focused on developing treatments for type 1 diabetes and other autoimmune diseases of the pancreas. Its pipeline includes compounds in preclinical development for autoimmune disorders of the liver and the skin, kidney conditions, and type 1 diabetes.
Classifications
AskAI Classifications
LabelsLinked Companies
